Katalog Plus
Bibliothek der Frankfurt UAS
Bald neuer Katalog: sichern Sie sich schon vorab Ihre persönlichen Merklisten im Nutzerkonto: Anleitung.
Dieses Ergebnis aus BASE kann Gästen nicht angezeigt werden.  Login für vollen Zugriff.

Exploring biomarkers of neurodegeneration in epilepsy: Critical insights

Title: Exploring biomarkers of neurodegeneration in epilepsy: Critical insights
Authors: Farhan, Rida; Hashmi, Syeda Amrah; Kapur, Jaideep; D'Abreu, Anelyssa; Punia, Vineet; Manning, Carol; Smith, Vanessa L.; Zawar, Ifrah
Contributors: American Epilepsy Society; Alzheimer's Association; BAND foundation; National Institutes of Health
Source: Epileptic Disorders ; volume 27, issue 3, page 341-357 ; ISSN 1294-9361 1950-6945
Publisher Information: Wiley
Publication Year: 2025
Collection: Wiley Online Library (Open Access Articles via Crossref)
Description: The advent of biofluid biomarkers for neurodegenerative disorders has precipitated a surge in recent evidence regarding their role in epilepsy. In this literature review, we examine the diagnostic, prognostic, and therapeutic potential of several biomarkers, including amyloid‐beta (Aβ) protein, total (t‐tau), phosphorylated tau (p‐tau) protein, alpha‐synuclein, neurofilament light chain (NfL), glial fibrillary acidic protein (GFAP), and others in epilepsy. Recent studies highlight mid‐life Aβ levels as a risk factor for late‐onset epilepsy. Several studies also show that amyloid pathology correlates with cognitive impairment in people with epilepsy (PWE). T‐tau and p‐tau levels in CSF and serum show diagnostic potential, particularly for temporal lobe epilepsy (TLE). Tau may also have significant prognostic utility in cognition of PWE and status epilepticus. Despite promising findings, larger prospective studies are needed to validate these biomarkers for routine clinical use in older PWE. Mouse models demonstrate tau's association with increased seizure susceptibility and mortality and the association of tau reduction with reduced seizure severity. This further highlights the need to investigate tau‐targeting therapies in future studies in older PWE. Recent small‐scale retrospective studies link NfL's role in cognitive impairment and status epilepticus, suggest a prognostic role of alpha‐synuclein in certain epilepsies, and propose emerging diagnostic and prognostic roles of other biomarkers in epilepsy, including GFAP, cytoskeletal proteins, and S100B. However, larger longitudinal studies are needed to confirm these findings. We propose integrating some of these biomarkers into clinical practice for selected older adults with epilepsy. This integration could improve diagnostic accuracy, prognosticate outcomes, and identify therapeutic targets that may improve seizure control and mitigate the progression of cognitive decline in PWE.
Document Type: article in journal/newspaper
Language: English
DOI: 10.1002/epd2.70023
Availability: https://doi.org/10.1002/epd2.70023; https://onlinelibrary.wiley.com/doi/pdf/10.1002/epd2.70023
Rights: http://creativecommons.org/licenses/by-nc-nd/4.0/
Accession Number: edsbas.4BC4E1D2
Database: BASE